269 related articles for article (PubMed ID: 24162378)
1. Mechanisms of action of tasquinimod on the tumour microenvironment.
Raymond E; Dalgleish A; Damber JE; Smith M; Pili R
Cancer Chemother Pharmacol; 2014 Jan; 73(1):1-8. PubMed ID: 24162378
[TBL] [Abstract][Full Text] [Related]
2. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
3. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
[TBL] [Abstract][Full Text] [Related]
4. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
5. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
7. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
George S; Pili R
Curr Oncol Rep; 2013 Apr; 15(2):65-8. PubMed ID: 23334511
[TBL] [Abstract][Full Text] [Related]
8. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Fan R; Satilmis H; Vandewalle N; Verheye E; Vlummens P; Maes A; Muylaert C; De Bruyne E; Menu E; Evans H; Chantry A; De Beule N; Hose D; Törngren M; Eriksson H; Vanderkerken K; Maes K; Breckpot K; De Veirman K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650020
[TBL] [Abstract][Full Text] [Related]
9. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Isaacs JT; Antony L; Dalrymple SL; Brennen WN; Gerber S; Hammers H; Wissing M; Kachhap S; Luo J; Xing L; Björk P; Olsson A; Björk A; Leanderson T
Cancer Res; 2013 Feb; 73(4):1386-99. PubMed ID: 23149916
[TBL] [Abstract][Full Text] [Related]
10. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson A; Nakhlé J; Sundstedt A; Plas P; Bauchet AL; Pierron V; Bruetschy L; Deronic A; Törngren M; Liberg D; Schmidlin F; Leanderson T
J Immunother Cancer; 2015; 3():53. PubMed ID: 26673090
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
13. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
[TBL] [Abstract][Full Text] [Related]
14. Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.
Nakhlé J; Pierron V; Bauchet AL; Plas P; Thiongane A; Meyer-Losic F; Schmidlin F
Oncoimmunology; 2016 Jun; 5(6):e1145333. PubMed ID: 27471612
[TBL] [Abstract][Full Text] [Related]
15. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
16. Tasquinimod targets suppressive myeloid cells in the tumor microenvironment.
Shen L; Pili R
Oncoimmunology; 2019; 8(10):e1072672. PubMed ID: 31646064
[TBL] [Abstract][Full Text] [Related]
17. Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.
Mehta AR; Armstrong AJ
Ther Adv Urol; 2016 Feb; 8(1):9-18. PubMed ID: 26834836
[TBL] [Abstract][Full Text] [Related]
18. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
19. Tasquinimod: a novel drug in advanced prostate cancer.
Osanto S; van Poppel H; Burggraaf J
Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
[TBL] [Abstract][Full Text] [Related]
20. A review of tasquinimod in the treatment of advanced prostate cancer.
Williamson SC; Hartley AE; Heer R
Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
